Apyx Medical Corp: Form 10-K for the period ended Dec 31, 2025
Filed with the SEC on Mar 10, 2026 and accepted by EDGAR at Mar 10, 2026, 13:11 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2025-01-01 to 2025-12-31 | $52.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2025-01-01 to 2025-12-31 | $19.8m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months2025-01-01 to 2025-12-31 | $33.0m | us-gaap:GrossProfit |
| Research and development | 12 months2025-01-01 to 2025-12-31 | $3.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2025-01-01 to 2025-12-31 | $15.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2025-01-01 to 2025-12-31 | −$6.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2025-01-01 to 2025-12-31 | $5.6m | us-gaap:InterestExpenseNonoperating |
| Income tax | 12 months2025-01-01 to 2025-12-31 | $270.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2025-01-01 to 2025-12-31 | −$11.2m | us-gaap:NetIncomeLoss |
| Basic EPS | 12 months2025-01-01 to 2025-12-31 | −$0.27 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 12 months2025-01-01 to 2025-12-31 | −$8.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2025-01-01 to 2025-12-31 | $1.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-12-31 | $31.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-12-31 | $58.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-12-31 | $66.8m | us-gaap:Assets |
| Current liabilities | At period end2025-12-31 | $11.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-12-31 | $52.0m | us-gaap:Liabilities |
| Long-term debt | At period end2025-12-31 | $34.8m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2025-12-31 | $14.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-26-007471. Last ingested by Listed: Oct 24, 2026, 14:56 ET. Listed shows no prices and gives no investment advice.